In Brief: Glaxo Wellcome's Wellbutrin SR
Executive Summary
Glaxo Wellcome's Wellbutrin SR: Sustained-release bupropion approved Oct. 4 in 50, 100 and 150 mg tablets for the treatment of depression. The drug, designated a "3S" approval, became "approvable" March 12 and has been pending at FDA since June 1994 ("The Pink Sheet" May 27, In Brief)...